Driftstatus

Nyheter i Janusmed

Janusmed

Driftstatus

Nyheter i Janusmed

omeprazol, Calquence (Kapsel, hård)
  • omeprazol
  • Calquence (Kapsel, hård)
Rensa sökning

10/16/2025

Janusmed interaktioner

Interaktioner

Startsida interaktioner

Aktuellt

Användarhandledning

E-utbildning

CYP3A4-hämmare/inducerare

FAQ

Skriv ut

Administreringssätt

Skriv ut

1 interaktion mellan valda läkemedel
Lägg till
Rensa tillval
Läkemedel / substans
Interaktioner
Calquence (Kapsel, hård)
akalabrutinib (Enteral peroral)

145

omeprazol (Enteral och parenteral)

113

C3 C3
C3 C3

akalabrutinib - omeprazol

akalabrutinib - omeprazol

Klass : C3

Visa all info

Skriv ut

Kontakta oss

  1. Calquence (acalabrutinib). AstraZeneca. SPC. 2020.

  2. Calquence (acalabrutinib). AstraZeneca. EPAR. 2020.

  3. FDA. Calquence (acalabrutinib), Astrazeneca MULTI-DISCIPLINE REVIEW. 2020

  4. Sharma S, Pepin X, Cheung J, et al. Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. Br J Clin Pharmacol. 2022 Oct;88(10):4573-84.

  5. Sharma S, Pepin X, Burri H, et al. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1294-307.

  1. Calquence (acalabrutinib). AstraZeneca. SPC. 2020.
  2. Calquence (acalabrutinib). AstraZeneca. EPAR. 2020.
  3. FDA. Calquence (acalabrutinib), Astrazeneca MULTI-DISCIPLINE REVIEW. 2020
  4. Sharma S, Pepin X, Cheung J, et al. Bioavailability of acalabrutinib suspension delivered via nasogastric tube in the presence or absence of a proton pump inhibitor in healthy subjects. Br J Clin Pharmacol. 2022 Oct;88(10):4573-84.
  5. Sharma S, Pepin X, Burri H, et al. Bioequivalence and Relative Bioavailability Studies to Assess a New Acalabrutinib Formulation That Enables Coadministration With Proton-Pump Inhibitors. Clin Pharmacol Drug Dev. 2022 Nov;11(11):1294-307.